Data from haemodynamic early phase clinical trials of GLP-1/glucagon dual agonists demonstrates Cotadutide (MEDI0382)16,17,98, Survodutide (BI 456906)19,99 and Mazdutide (IBI362)100 increase heart rate and reduce blood pressure in patients with T2D or obesity. The gene discussed is GLP1R; the disease is obesity disorder.